poor prognosis
Showing 1 - 25 of >10,000
Low Back Pain, Chronic Low-back Pain, Back Pain Trial (Control, Yoga)
Not yet recruiting
- Low Back Pain
- +3 more
- Control
- Yoga
- (no location specified)
Jul 18, 2023
Acute Myeloid Leukemia (AML) Trial in Nantes (Siltuximab)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
-
Nantes, FranceCHU de Nantes
Jan 24, 2023
Squamous Cell Carcinoma of the Head and Neck Trial in Ann Arbor (Cisplatin, Carboplatin, IMRT (Intensity-Modulated Radiation
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Cisplatin
- +3 more
-
Ann Arbor, Michigan
- +1 more
Dec 20, 2022
Chronic Kidney Disease-related Sarcopenia With Poor Prognosis
Recruiting
- Chronic Kidney Diseases
- Sarcopenia
- No intervention
-
Guangzhou, Guangdong, ChinaNanfang Hospital, Southern Medical University
May 9, 2022
Non-Seminomatous Germ Cell Tumor Trial in Villejuif (BEP Protocol, Dose-dense regimen, Early tumor resection or HD-CT)
Not yet recruiting
- Non-Seminomatous Germ Cell Tumor
- BEP Protocol
- +2 more
-
Villejuif, FranceGustave Roussy
Jan 27, 2023
Prognosis Evaluation of Sepsis:Single-center, Retrospective
Not yet recruiting
- To Clarify and Verify the Value of NLR in the Diagnosis and Poor Prognosis of Sepsis.c
- No intervention
- (no location specified)
Nov 22, 2022
Intracerebral Hemorrhage Trial in Xi'an (No intervention)
Recruiting
- Intracerebral Hemorrhage
- No intervention
-
Xi'an, Shaanxi, ChinaTandu Hospital, Fourth Military Medical University
Jan 16, 2022
Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous
Active, not recruiting
- Epidermotropic T-cell Lymphomas
- HSCT
- Standard Care
-
Paris, FranceSaint Louis hospital
Apr 15, 2022
Carcinoma of Unknown Primary Trial in Calgary, Edmonton, Ottawa (Pembrolizumab Injection)
Recruiting
- Carcinoma of Unknown Primary
- Pembrolizumab Injection
-
Calgary, Alberta, Canada
- +2 more
Feb 18, 2022
Advanced or Poor Prognosis Cancers
Active, not recruiting
- Cancer
-
La Jolla, California
- +1 more
Feb 17, 2022
Glomerulonephritis, IGA Trial in Besançon (Blood collection, Urine sample)
Not yet recruiting
- Glomerulonephritis, IGA
- Blood collection
- Urine sample
-
Besançon, FranceCentre Hospitalier Universitaire de Besançon
Mar 17, 2023
Infertility Trial in Jinan (Double Stimulation Protocol, Antagonist Stimulation Protocol)
Not yet recruiting
- Infertility
- Double Stimulation Protocol
- Antagonist Stimulation Protocol
-
Jinan, Shandong, ChinaShandong University
Mar 12, 2023
Unresectable Sinonasal Tumors Trial in Italy (Cisplatin, Docetaxel, 5-fluorouracil)
Active, not recruiting
- Unresectable Sinonasal Tumors
- Cisplatin
- +9 more
-
Brescia, BS, Italy
- +4 more
Apr 8, 2022
Cancer Trial in Lexington (Therapeutic Intervention)
Recruiting
- Cancer
- Therapeutic Intervention
-
Lexington, KentuckyMarkey Cancer Center, University of Kentucky
Nov 18, 2022
Acute Myeloid Leukemia (AML) Trial in Nantes (Tocilizumab)
Active, not recruiting
- Acute Myeloid Leukemia (AML)
-
Nantes, FranceCHU of Nantes
Dec 16, 2022
Fertility Disorders Trial in Brussels (CFA-double pick up)
Recruiting
- Fertility Disorders
- CFA-double pick up
-
Brussels, Jette, BelgiumUZ Brussel
Aug 4, 2021
Poor Prognosis in Acute Ischemic Stroke:Multi-center Study
Recruiting
- Acute Ischemic Stroke
-
Guanzhou, Guangdong, ChinaDepartment of Neurology, NanFang Hospital, Southern Medical Univ
Nov 11, 2021
Summary of Infants Weighing 500 Grams or Less
Active, not recruiting
- Infant, Extremely Low Birth Weight
- Microcephaly
- Microcephaly
-
Azumino, Nagano, JapanNagano Children's Hospital
Apr 29, 2022
Hepatocellular Carcinoma Trial in Bobigny (Lenvatinib Pill)
Recruiting
- Hepatocellular Carcinoma
- Lenvatinib Pill
-
Bobigny, FranceNAHON
Apr 6, 2022
Optimized Peak VO2 in Predicting Advanced HF
Completed
- Heart Failure
- +2 more
- cardiopulmonary exercise test
- (no location specified)
Jan 16, 2022
Cognitive Impairment and Poor Prognosis After Ischemic Stroke
Recruiting
- Ischemic Stroke
-
Guanzhou, Guangdong, ChinaDepartment of Neurology, NanFang Hospital, Southern Medical Univ
Jul 29, 2021